Venture Life Group (LSE:VLG), the AIM-quoted consumer self-care company, published results for a 17-month period showing continuing Revenue of £50.0m and a net cash position, and said founder and Chief Executive Jerry Randall will retire as CEO at the end of 2026, to be succeeded by Chief Financial Officer Daniel Wells.

What Venture Life announced

Venture Life released its final results and a CEO succession update at 07:00 on 29 September 2026. The results cover a 17-month period to 31 May 2026, after the company moved its accounting reference date from 31 December. The comparative figures are for the 12 months to 31 December 2024, so the two periods are not directly like for like.

Revenue from continuing operations was £50.0m, against £26.6m, with underlying growth of 16.0% on a proforma basis. Adjusted EBITDA from continuing operations rose to £7.9m from £6.2m, although the Margin fell to 15.7% from 23.2%. Continuing operations recorded an operating loss of £3.8m, compared with a profit of £1.5m, while group profit after tax was £3.4m, against a loss of £0.3m.

CEO succession at Venture Life

The company said Jerry Randall "has notified the Board of his future intention to retire from the role of CEO, with effect from 31 December 2026". Daniel Wells, the current CFO, will take over from 1 January 2027. Randall will remain a director until 31 May 2027 and then act as an adviser to the Board and senior management. The Board said it is "progressing the appointment of the CFO successor in accordance with its established succession plans and processes".

Wells said: "It is a privilege to be taking on the role of CEO from 1 January 2027, succeeding our CEO and Founder, Jerry Randall." Randall said: "This has been a momentous period for Venture Life."

Balance sheet, deals and buybacks

Venture Life ended the period with cash of £11.5m and no drawn debt, compared with net Debt of £18.7m at the end of 2024. It has an undrawn £30m revolving Credit Facility plus a £20m accordion. During the period it sold its CDMO Business at a €62m Enterprise value and its oral care brands at a £4.5m enterprise value.

After the period end, it completed the Acquisition of the FemiClear and CUROXEN brands on 2 June 2026 "for an initial consideration of $23.0 million and up to an additional $5.0 million of deferred contingent consideration". The company returned £4.7m through share Buybacks during the period and a further £2.4m afterwards, taking the total to £7.1m for 10.6m shares.

Risks for investors to consider

The shift from a profitable continuing operating line to an operating loss, and the lower adjusted EBITDA margin, are points shareholders may weigh. A change of chief executive and a search for a new CFO at the same time adds execution risk. The company also referred to "prevailing market conditions", and integration of the US brands acquired after the period end will be a further test.

What investors may watch next

The Board said it has "aspirations to achieve annual revenue in excess of £300 million within the next five years" and expects an adjusted EBITDA margin of about 25% at that scale. Investors in AIM stocks may watch for the CFO appointment, trading updates and progress in women's intimate and hormonal health across the UK and US.

Where Venture Life stands now

The company said it closed the period "with financial results in line with market expectations" and, with its current balance sheet, is "well placed to navigate this environment". For followers of UK shares, the Leadership handover and the new financial year are the next markers on the London Stock Exchange.